FDA eases medication guide distribution requirements
- Don't get burned by OTC topical analgesics. Derbis, Janelle // Pharmacy Today;Nov2012, Vol. 18 Issue 11, p59
The article reports that the U.S. Food and Drug Administration (FDA) has identified cases of skin injuries with the use of over the counter (OTC) topical muscle and joint pain relievers containing menthol, methyl salicylate, or capsaicin. It notes that the cases of skin injuries ranged from...
- Acetaminophen Update. McMann, Mary Carole // Nurse Practitioner World News;Jan/Feb2012, Vol. 17 Issue 1/2, p13
The article reports on the measure taken by the U.S. Food and Drug Administration (FDA) to increase the safety of using acetaminophen. It states that the FDA required a warning for prescription medications involving acetaminophen to provide information about the risk of liver damage due to...
- FDA's safety reform is greeted with scepticism. Moynihan, Ray // BMJ: British Medical Journal (International Edition);2/26/2005, Vol. 330 Issue 7489, p435
Reports that a new safety body at the United States Food and Drug Administration is being met with some scepticism by critics. The new drug safety oversight board whose job it will be the oversee the management of drug safety issues and to provide information to doctors and patients more...
- Educating patients about FDA's MedWatch. Tanzi, Maria G. // Pharmacy Today;Mar2013, Vol. 19 Issue 3, p26
The article focuses on patients education on MeWatch Adverse Reporting Program of the U.S. Food and Drug Administration (FDA). It says that the program determines medical products safety hazard signals, and MedWatch reports regarding adverse events linked with use of FDA-regulated drugs can be...
- FDA adds boxed warning to propylthiouracil. Kalwaitis, Katie; Southall, Jennifer // Endocrine Today;May2010, Vol. 8 Issue 5, p1
The article reports that the U.S. Food and Drug Administration (FDA) has added a boxed warning to propylthiouracil to include risks of severe liver injury and acute liver failure.
- Advisory panel votes against Qnexa. // OB/GYN Clinical Alert;Sep2010 Pharmacology, p2
The article discusses the disapproval of the weight-loss drug Qnexa by the U.S. Food and Drug Administration (FDA) due to its side effects such as depression, sleep disorders, and other cognitive disorders.
- Antidote. Siegel, Marc // Medical Marketing & Media;Jul2011, Vol. 46 Issue 7, p12
The article focuses on the disadvantage in media-generated hype mentioning the move of the U.S. Food and Drug Administration in announcing the side effects associated in taking the 80 milligram (mg) simvastatin which may cause panic and fear towards using the drug.
- First reports of serious adverse drug reactions in recent weeks. // Drugs & Therapy Perspectives;Dec2010, Vol. 26 Issue 12, p22
A chart is presented which lists serious adverse drug reactions which were reported in 2010, including reactions which were reported for the drugs amrubicin, cabergoline and clarithromycin.
- MuckReads Podcast: When Diet Drugs Harm Instead of Help. Bronzan, Nicole Collins // Pro Publica;Apr2015, p1
The article introduces a podcast on an investigative report which found that in the last three years, the U.S. Food and Drug Administration (FDA) has approved five new drugs on the market that are potentially harmful.